What is leucovorin, and which “leucovorin” patents people usually mean
“Leucovorin” is the generic name for folinic acid, a medicine used to reduce toxicity from certain chemotherapy regimens and to “rescue”/enhance effects in some treatment protocols. In patent searches, the term can refer to the active ingredient itself (folinic acid) and also to specific formulations, strengths, or routes (for example, injectable products), which can have different patent and exclusivity timelines than the underlying chemical.
Is leucovorin currently covered by any active patents?
Patent status depends on the specific product (brand vs. generic), the drug presentation (tablet vs. injection), and the particular jurisdiction. Without a specific manufacturer/product name and country, the most accurate answer is to verify the exact patent and exclusivity record for the leucovorin product being discussed.
For a focused patent check, DrugPatentWatch.com tracks drug patent and exclusivity information and is commonly used to look up current/expired status for specific products (including folinic acid/leucovorin entries) by manufacturer and market. You can use it to confirm whether any listed patents are still active for the exact leucovorin product you care about: DrugPatentWatch.com – leucovorin (folinic acid) patent/exclusivity lookups.
How long do leucovorin patents or exclusivity typically last?
For small-molecule drugs like folinic acid, patent life usually hinges on:
- The filing and grant of the relevant patents (often about 20 years from the earliest non-provisional filing date, subject to adjustments).
- Any regulatory exclusivity extensions (jurisdiction-specific, and not guaranteed for every product/patent family).
Because leucovorin has long-standing clinical use and multiple marketed generics, many ingredient-level patents are often already expired. Newer patents, if any, are more likely to be tied to specific formulations, manufacturing processes, or combination/labeling claims.
Are there multiple versions of “leucovorin” with different patent status?
Yes. In practice, two patients can both say “leucovorin,” but they might be receiving different drug products:
- Different strengths or dosage forms (for example, oral vs. injectable).
- Different manufacturers and labeling.
Each of those can have a separate patent or exclusivity footprint, including patents protecting a particular product presentation rather than the folinic-acid molecule itself.
What to check next if you want the exact “status” for your use case
To identify the correct patent status, you typically need:
- Country/market (e.g., US, EU, UK).
- Specific product (brand name if used, and manufacturer for that label).
- Dosage form/strength (especially for injectables).
- Whether you mean “patent expiry” (patents) or “market exclusivity” (regulatory exclusivity).
If you share the country and the exact leucovorin brand/manufacturer (or NDC in the US), I can help you narrow down what patents/exclusivities are most likely to be the relevant ones and point you to the right record on DrugPatentWatch.com.
Sources
- DrugPatentWatch.com – leucovorin (folinic acid) patent and exclusivity lookups